AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MU, MHLD, DPLO and AMRN

February 26, 2019

CEDARHURST, N.Y., Feb. 26, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Micron Technology Inc. (NASDAQGS: MU)Investors Affected: September 26, 2017 - November 19, 2018

A class action has commenced on behalf of certain shareholders in Micron Technology Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company engaged in anti-competitive behavior, including artificially restricting supply growth of DRAM; (2) these anti-competitive efforts were reasonably likely to lead to regulatory scrutiny; (3) the Company’s anti-competitive efforts artificially boosted its operating metrics; (4) as a result, the Company’s financial performance, including revenue, was overstated; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kseclaw.com/securities/micron-technology-inc/?wire=3

Maiden Holdings, Ltd. (NASDAQGS: MHLD)Investors Affected: March 4, 2014 - November 9, 2018

A class action has commenced on behalf of certain shareholders in Maiden Holdings, Ltd. The complaint alleges that during the Class Period, defendants misrepresented the quality and nature of Maiden’s underwriting and risk management policies and practices and the risks of its reinsurance portfolio. In particular, defendants misleadingly claimed that they were subjecting AmTrust’s insurance portfolio to robust analysis and cross-checks to ensure that the Company had appropriately priced the risk of reinsuring AmTrust’s insurance portfolio. In truth, the Company had failed to employ sufficient underwriting and risk management protocols and had largely abdicated its responsibility to ensure that its AmTrust Reinsurance segment priced policies commensurate with the risk assumed by the Company.

Shareholders may find more information at https://kclasslaw.com/securities/maiden-holdings-ltd-loss-submission-form/?wire=3

Diplomat Pharmacy, Inc. (NYSE: DPLO)Investors Affected: February 26, 2018 - February 21, 2019

A class action has commenced on behalf of certain shareholders in Diplomat Pharmacy, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Diplomat had downplayed its success in integrating and growing its PBM business, which included LDI Integrated and National Pharmaceutical, two companies Diplomat had acquired in late 2017; (2) consequently, Diplomat would need to record a non-cash impairment charge upwards of approximately $630 million relating to its PBM business and these 2017 acquisitions; (3) due to the foregoing, Diplomat would withdraw its preliminary 2019 full-year outlook issued less than seven weeks prior; and (4) as a result, defendants’ statements about Diplomat’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/diplomat-pharmacy-inc-loss-submission-form/?wire=3

Amarin Corporation (NASDAQGM: AMRN)Investors Affected: September 24, 2018 - November 9, 2018

A class action has commenced on behalf of certain shareholders in Amarin Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/amarin-corporation-loss-submission-form/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock.

CONTACT:Kuznicki Law PLLCDaniel Kuznicki, Esq.445 Central Avenue, Suite 334Cedarhurst, NY 11516Email: dk@kclasslaw.comPhone: (347) 696-1134Cell: (347) 690-0692Fax: (347) 348-0967